Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$613.00K$613.00Kderived+20.4% vs Q4 2018 Net Income-$819.00K-$819.00KderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$822,000N/M Operating Cash Flowderived-$656,000N/M Free Cash Flowderived-$657,000N/M Margins · derivedOperating margin-134.1%+136.2 pt vs Q4 2018
Net margin-133.6%+138.3 pt vs Q4 2018
ended Jul 31, 2019 · filed Oct 30, 2019 · 91 d after period end